Expression of c-erbB-2 and p53 in Breast Carcinoma Patients: Comparison with Traditional Prognostic Factors and Survival

Gurkan, Alihan; Erdoğan, Gülgün; Erdoğan, Okan; Peştereli, Elif; Öğüş, Mehmet; Karaveli, Şeyda; Çolak, Taner

doi:10.1177/147323000403200502

Cited by 5 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study p53 immunostaining was positive in 38.3%. However others reported different results (7,8,9). Our study showed a significant inverse correlation with increasing age (p=0.001), with higher expression being found in younger patients and lower expression in older age group.…”

Section: Discussionsupporting

confidence: 47%

P53 in breast carcinoma: an immunohistochemical study

Saleem¹,

Aziz²

2011

Ann Coll Med Mosul

View full text Add to dashboard Cite

Objectives:The aims of the present study are; first, to find out the relative frequency of p53 overexpression in different types of breast cancer. Second, to correlate the p53 over-expression with different parameters, including the age and menopausal status of the patient, size, grade, stage, type of the tumor, and the status of axillary lymph nodes. Third, to compare our results with others Methods: The study was both pro and retrospective and included 60 cases of breast carcinoma. Data were obtained from archives of the pathology department, at Al-jumhuri Teaching Hospital and collected in a period spanning from August 2008 to January 2009. P53 over-expression was assessed immunohistochemically . Results: The patients ages ranged from 25 to 78 years (mean: 51.5 year); most of them were in the fourth decade (41.2%). There was a significant inverse relation between p53 over-expression and the age of the patients (p<0.001), in which the largest percentage of p53 positivity seen in the third decade. P53 over-expression was detected in 38.3% of the cases. P53 over-expression was found in (100%) of medullary carcinoma, 19/47 (40.4%) of invasive ductal carcinoma (NOS), 1/3 (33.3%) of ductal carcinoma in situ, and 1/6 (1.7%) of invasive lobular carcinoma. P53 over-expression was not detected in mucinous and papillary carcinomas.There was a significant direct correlation between p53 over-expression and tumor size (p=0.0274), grade (p=0.032), and stage (p<0.001).There were no statistically significant relations between p53 over-expression and the menopausal status (p=0.262) or axillary lymph node metastasis (p=0.471). Conclusions: Immunopositivity for p53 tumor suppressor protein was detected in 38.3% of the cases in this study. P53 over-expression was significantly correlated with patient's age, tumor grade, stage, and size, but no correlation was found with menopausal status and axillary lymph node metastasis.

show abstract

Section: Discussionsupporting

confidence: 47%

P53 in breast carcinoma: an immunohistochemical study

Saleem¹,

Aziz²

2011

Ann Coll Med Mosul

View full text Add to dashboard Cite

show abstract

“…The co-expression of TP53 protein and ERBB2 has been extensively studied as prognostic indicator for breast cancer mainly using IHC based methods [8][9][10][11][12][13][14][15][16][17]. However, discrepancies among the study results exist, probably due to the qualitative and quantitative differences in the interpretation of IHC results.…”

Section: Survival Comparisons By Tp53 Mutation Type and Erbb2 Amplifimentioning

confidence: 99%

“…Genetic alterations of TP53 and ERBB2 are among the most common abnormalities in breast tumors, and they have been extensively studied as prognostic indicators for breast cancer. Over-expression of ERBB2 and expression of mutant TP53 proteins (mutations in TP53) have been shown to have prognostic value individually; however the prognostic significance of their co-existence in the same tumor is still controversial [8][9][10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer

Özçelik

Pinnaduwage

Bull

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

Alterations of TP53 and ERBB2 have been shown to play important roles in the prognosis of breast cancer. The primary objective of this study is to characterize TP53 mutation types in node negative breast cancer and investigate their prognostic value, alone and in combination with ERBB2 amplification status. TP53 mutational status (exons 2-10) and ERBB2 amplification status were determined in tumor specimens from a prospective cohort of 543 women with node-negative breast cancer. During a median follow-up of 120 months, there were 111 disease recurrences, and 81 disease-related deaths (3 with cancer; 78 from cancer). Of 543 women, 133 (24.5%) carried mutations in exons 4-9 of the TP53 gene. Seventy-one (53.4%) of these mutations were missense; whereas 62 (46.6%) were protein-truncating mutations. Women whose tumors had missense TP53 mutations were found to be at significantly higher risk of recurrence and death compared to those with wild type TP53, and they also tended to have worse prognosis compared to those with truncating mutations. Those with short truncated proteins tended to have good prognosis compared to those with long truncated proteins, but the risk of recurrence and death did not differ between those whose tumors exhibited conserved versus non-conserved mutations. Missense mutations, in combination with ERBB2 amplification, were observed in 4.6% of the tumors and dramatically affected the disease-specific survival (DSS) and disease-free survival (DFS) of the breast cancer patients. Our study suggests that the type of TP53 mutation, especially missense mutation, is a strong prognostic indicator for DFS and DSS in node-negative breast cancer, particularly in combination with ERBB2 amplification.

show abstract

“…The p53 protein plays a pivotal role in the cellular response to DNA-damaging events. P53 overexpression has been correlated with higher histological breast tumour grade and lower overall and disease-free survival in breast cancer patients (Gurkan et al 2004). Bcl-2 positivity in breast tumours entails a more favourable clinical course with lower frequency of lymph node metastasis and longer survival, whereas this suggestion may not apply to the pleomorphic lobular carcinoma subtype which is a variant of ILC characterized by poor prognosis (Frolik et al 2001).…”

Section: Biological and Clinical Features Of Invasive Lobular Cancermentioning

confidence: 98%

Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment

Biglia¹,

Mariani²,

Sgrò³

et al. 2007

Endocr Relat Cancer

View full text Add to dashboard Cite

A growing body of evidence support the association between the use of hormone replacement therapy (HRT) and a higher risk of both invasive lobular carcinoma (ILC) and invasive ductal-lobular mixed carcinoma (IDLC). Overall biological and clinical features of ILC entail a more cautious diagnostic and therapeutic approach as compared with invasive ductal carcinoma (IDC). ILCs are more frequently multifocal, multicentric and/or bilateral. Mammography and ultrasound show, therefore, significant limitations, while the higher sensitivity of magnetic resonance imaging in the detection of multifocal and/or multicentric lesions seems to improve the accuracy of preoperative staging of ILCs. Early diagnosis is even more challenging because the difficult in the localization and the sparse cellularity of lobular tumours may determine a false negative core biopsy. ILC is characterized by low proliferative activity, C-ErbB-2 negativity, bcl-2 positivity, p53 and VEGF negativity, oestrogen and progesterone positive receptors, low grade and low likelihood of lymphaticvascular invasion. However, this more favourable biological behaviour does not reflect into a better disease-free and overall survival as compared with IDC. Since lobular histology is associated with a higher risk of positive margins, mastectomy is often preferred to breast conservative surgery. Moreover, only few patients with ILC achieve a pathologic response to preoperative chemotherapy and, therefore, in most patients mastectomy can be regarded as the safer surgical treatment. The preoperative staging and the follow-up of patients with ILC are also complicated by the particular metastatic pattern of such histotype. In fact, metastases are more frequently distributed to the gastrointestinal tract, peritoneum/retroperitoneum and gynaecological organs than in IDC.

show abstract

Expression of c-erbB-2 and p53 in Breast Carcinoma Patients: Comparison with Traditional Prognostic Factors and Survival

Cited by 5 publications

References 24 publications

P53 in breast carcinoma: an immunohistochemical study

P53 in breast carcinoma: an immunohistochemical study

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer

Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment

Contact Info

Product

Resources

About